These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 23483375)

  • 21. Clearing the fog: a review of the effects of dietary omega-3 fatty acids and added sugars on chemotherapy-induced cognitive deficits.
    Orchard TS; Gaudier-Diaz MM; Weinhold KR; Courtney DeVries A
    Breast Cancer Res Treat; 2017 Feb; 161(3):391-398. PubMed ID: 27933449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy.
    Mehnert A; Scherwath A; Schirmer L; Schleimer B; Petersen C; Schulz-Kindermann F; Zander AR; Koch U
    Patient Educ Couns; 2007 Apr; 66(1):108-18. PubMed ID: 17320337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroepidemiology of cancer and treatment-related neurocognitive dysfunction in adult-onset cancer patients and survivors.
    Jean-Pierre P; McDonald BC
    Handb Clin Neurol; 2016; 138():297-309. PubMed ID: 27637965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive changes in cancer survivors. Cancer and cancer treatment often cause cognitive deficits, but no guidelines exist for screening or treatment.
    Nail LM
    Am J Nurs; 2006 Mar; 106(3 Suppl):48-54. PubMed ID: 16481853
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'.
    Raffa RB; Tallarida RJ
    J Clin Pharm Ther; 2010 Jun; 35(3):249-55. PubMed ID: 20831527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognitive speed of processing and functional declines in older cancer survivors: an analysis of data from the ACTIVE trial.
    Kvale EA; Clay OJ; Ross-Meadows LA; McGee JS; Edwards JD; Unverzagt FW; Ritchie CS; Ball KK
    Eur J Cancer Care (Engl); 2010 Jan; 19(1):110-7. PubMed ID: 19709169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies.
    Pellacani C; Eleftheriou G
    Adv Med Sci; 2020 Sep; 65(2):265-285. PubMed ID: 32361484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies.
    Beijers AJ; Jongen JL; Vreugdenhil G
    Neth J Med; 2012 Jan; 70(1):18-25. PubMed ID: 22271810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [An overview of the research of cancer-related cognitive impairment].
    Ferencz V; S Nagy Z; Tóth M
    Orv Hetil; 2019 Sep; 160(38):1495-1502. PubMed ID: 31537098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy.
    Wang XM; Walitt B; Saligan L; Tiwari AF; Cheung CW; Zhang ZJ
    Cytokine; 2015 Mar; 72(1):86-96. PubMed ID: 25573802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant chemotherapy for breast cancer and cognitive impairment.
    Marín AP; Sánchez AR; Arranz EE; Auñón PZ; Barón MG
    South Med J; 2009 Sep; 102(9):929-34. PubMed ID: 19668023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood Osteosarcoma.
    Edelmann MN; Daryani VM; Bishop MW; Liu W; Brinkman TM; Stewart CF; Mulrooney DA; Kimberg C; Ness KK; Cheung YT; Srivastava DK; Robison LL; Hudson MM; Krull KR
    JAMA Oncol; 2016 Feb; 2(2):201-8. PubMed ID: 26583357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early and late long-term effects of adjuvant chemotherapy.
    Mayer EL
    Am Soc Clin Oncol Educ Book; 2013; ():9-14. PubMed ID: 23714443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is chemotherapy associated with cognitive impairment?
    Zachariae R; Mehlsen MY
    Nat Rev Urol; 2011 Apr; 8(4):182-3. PubMed ID: 21475329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer 'survivor-care': II. Disruption of prefrontal brain activation top-down control of working memory capacity as possible mechanism for chemo-fog/brain (chemotherapy-associated cognitive impairment).
    Raffa RB
    J Clin Pharm Ther; 2013 Aug; 38(4):265-8. PubMed ID: 23656522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain vulnerability to chemotherapy toxicities.
    Ahles TA
    Psychooncology; 2012 Nov; 21(11):1141-8. PubMed ID: 23023994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The phenomenon of chemo brain.
    Staat K; Segatore M
    Clin J Oncol Nurs; 2005 Dec; 9(6):713-21. PubMed ID: 16381547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer.
    de Ruiter MB; Reneman L; Boogerd W; Veltman DJ; van Dam FS; Nederveen AJ; Boven E; Schagen SB
    Hum Brain Mapp; 2011 Aug; 32(8):1206-19. PubMed ID: 20669165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge.
    Kandula T; Park SB; Cohn RJ; Krishnan AV; Farrar MA
    Cancer Treat Rev; 2016 Nov; 50():118-128. PubMed ID: 27664395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemo fog: cancer chemotherapy-related cognitive impairment. Preface.
    Raffa RB; Tallarida RJ
    Adv Exp Med Biol; 2010; 678():vii-viii. PubMed ID: 20737998
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.